Azimilide

Drug Profile

Azimilide

Alternative Names: NE-10064; Stedicor

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Procter & Gamble
  • Developer Allergan; Blue Ash Therapeutics; Mitsubishi Tanabe Pharma Corporation; Procter & Gamble
  • Class Class III antiarrhythmics; Imidazolidines; Piperazines
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ventricular arrhythmias
  • No development reported Arrhythmias; Atrial fibrillation; Atrial flutter; Postmyocardial infarction; Supraventricular arrhythmias

Most Recent Events

  • 11 Aug 2015 Azimilide is still in phase III development for Ventricular arrhythmias in USA
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top